scholarly journals Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers

2021 ◽  
Author(s):  
Maria Elena Romero-Ibarguengoitia ◽  
Diego Rivera-Salinas ◽  
Yodira Guadalupe Hernandez-Ruiz ◽  
Ana Gabriela Armendariz-Vazquez ◽  
Arnulfo Gonzalez-Cantu ◽  
...  
Keyword(s):  
Side Effects ◽  
Healthcare Workers ◽  
Booster Dose ◽  
Common Side Effect ◽  
Igg Antibody ◽  
Humoral Immune ◽  
The Third ◽  
Antibody Titers ◽  
Original Scheme ◽  
Prospective Longitudinal

Background: Vaccination is our main strategy to control SARS-CoV-2 infection. Given a decrease in the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months following the second BNT162b2 dose, healthcare workers got a third booster dose after six months of completing the original scheme. This study aimed to analyze quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and safety of the third dose. Material and methods: A prospective longitudinal cohort study included healthcare workers who received a third booster dose after six months of the complete BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the complete scheme, 1-7 days following the third dose, and 21-28 days after the boost. Results: The cohort comprised 168 non-immunocompromised participants of 41(10) years old, 67% being women. The third dose was associated with increasing the quantitative antibody titers, regardless of previous SARS-CoV-2 history. In negative SARS-CoV-2 history, the median (IQR) antibody titers increased from 379 (645.4) to 2960 (2010), while in positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080). The third dose had less number of total side effects compared to the other two shots. The most common side effect after the third BNT162b2 shot was pain at the injection site (n=82, 84.5%), followed by tiredness (n=45, 46.4%), with a mild severity (n=36, 37.1%). Tiredness, myalgias, arthralgias, fever, and adenopathy were proportionally higher following the third dose than the two-dose regimen (p<0.05). Conclusion: The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated with no severe side effects after the additional BNT162b2 dose.

COMBINED IMMUNIZATION AGAINST DIPHTHERIA, TETANUS AND PERTUSSIS IN NEWBORN INFANTS

PEDIATRICS ◽  
1949 ◽  
Vol 3 (2) ◽  
pp. 181-194
Author(s):  
PAUL A. DI SANT'AGNESE
Keyword(s):  
Booster Dose ◽  
Newborn Infants ◽  
Active Immunization ◽  
Striking Difference ◽  
Tetanus Antitoxin ◽  
The Third ◽  
Number Of Patients ◽  
Diphtheria Antitoxin ◽  
Antibody Titers ◽  
One Year

Additional serologic studies are presented of a group of newborn infants whose antibody production following combined prophylactic inoculation against tetanus, diphtheria and pertussis was reported in a previous paper. Duration of Antibody Titers: In the 10 months following the last injection of triple combined antigen a steady decline in diphtheria antitoxin titers was observed which was more marked in patients who had achieved high antibody levels. A similar decrease was found in the percentage of infants with high titers of tetanus antitoxin, but there were no cases whose tetanus antitoxin level dropped to less than the "protective" titer (0.1 unit/cc.). Progressive decrease in diphtheria and tetanus antitoxin titers with passage of time is in agreement with findings of others. After the third and last immunizing injection, a rapid initial decrease was noted in the number of patients with "protective" pertussis agglutinin titers (1:400 or higher); then a levelling off took place and no further change was noted in the next six months. On the other hand, a steady decline was found in the percentage of infants with "high" agglutinin levels (1:3200). To our knowledge this has not been observed before. The young age of our patients at the time of the basic injections may have been responsible for the findings. Antibody Titers After Booster Dose: One group of infants was reinjected at the age of six months (four months after the third and last immunizing injection), another group at one year of age (10 months after the last injection). All booster doses consisted of 0.5 cc. of the same triple combined antigen used in basic immunization. After booster a marked increase was noted in diphtheria antitoxin titers to a level higher than that observed following the basic immunizing injections. Tetanus antitoxin response was considered to have been equally good, although more difficult to evaluate because of the high antitoxin levels present before reinjection. In the case of pertussis agglutinins, it appeared as if there were a "ceiling" of about 60% of infants who could, even after reinjection, develop a "protective" agglutinin titer (1:400 or higher). A striking difference was observed in both pertussis agglutinin levels and diphtheria antitoxin titers achieved by infants reinjected at six months and one year of age. This was thought to be due to immaturity of the immune mechanisms in the younger age group. An added factor in the case of diphtheria antitoxin in some patients may have been the persistence of passive antibodies acquired transplacentally. Antibody titers also were determined six months after booster dose in the infants who had been reinjected at the age of six months. A marked decrease was observed in the percentage of patients with "protective" pertussis agglutinin titers and "high" (1.0 unit/cc.) diphtheria antitoxin levels. No reduction was noted in tetanus antitoxin titers. Effects of Passive immunity to Diphtheria on Active immunization with Diphtheria Toxoid: With only one exception, all infants tested after a booster dose had been administered between 6 and 12 months of age had "protective" diphtheria antitoxin titers (0.03 units/cc. or more). Active immunization against diphtheria was therefore considered to have been achieved in all cases (with one exception) despite the passively transmitted antitoxin present at birth in over half the cases. While passive diphtheria antitoxin present at birth did not prevent "sensitization" of the antibody-forming tissues to the diphtheria antigen, it did decrease significantly the amounts of antitoxin actively produced in response to basic inoculation. Reasons for the success of active diphtheria immunization in this series are discussed. Arguments against active immunization of mothers in pregnancy for protection of their offspring are considered.

scholarly journals Effect of a booster-dose of rabies vaccine on the duration of virus neutralizing antibody titers in bovines

1998 ◽  
Vol 31 (4) ◽  
pp. 367-371 ◽  
Author(s):  
Avelino Albas ◽  
Paulo Eduardo Pardo ◽  
Albério Antonio Barros Gomes ◽  
Fernanda Bernardi ◽  
Fumio Honma Ito
Keyword(s):  
Immune Response ◽  
Neutralizing Antibodies ◽  
Booster Dose ◽  
Neutralization Test ◽  
Neutralizing Antibody ◽  
Rabies Vaccine ◽  
Western Region ◽  
Humoral Immune ◽  
Paulo State ◽  
Antibody Titers

Humoral immune response using inactivated rabies vaccine was studied in 35 nelore cross-bred bovines of western region of São Paulo state. Ninety days after vaccination, 13 (92.8%) animals presented titers 30.5IU/ml, through mouse neutralization test. After 180 days, 9 (64.3%) sera showed titers 30.5IU/ml, after 270 days, only one (7.1%) showed a titer of 0.51IU/ml, and after 360 days, all animals showed titers < 0.5IU/ml. Group of animals receiving booster dose 30 days after vaccination presented, two months after, all with titers > 0.5IU/ml. At 180 days, 17 (80.9%) sera presented titers > 0.5IU/ml; at 270 days, 15 (71.4%), with titers 30.5IU/ml and at 360 days, 4 (19.0%), with titers 30.5IU/ml. Booster-dose ensured high levels of neutralizing antibodies for at least three months, and 240 days after revaccination, 71.4% of animals were found with titers 30.5IU/ml.

scholarly journals Use of heat-not-burn tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers

2021 ◽  
Author(s):  
Shohei Yamamoto ◽  
Akihito Tanaka ◽  
Norio Ohmagari ◽  
Koushi Yamaguchi ◽  
Kazue Ishitsuka ◽  
...  
Keyword(s):  
Alcohol Consumption ◽  
Alcohol Drinking ◽  
Healthcare Workers ◽  
Smoking Status ◽  
Geometric Mean ◽  
Tobacco Product ◽  
Igg Antibody ◽  
Tobacco Products ◽  
Product Use ◽  
Antibody Titers

Background: The effect of heat–not–burn (HNB) tobacco product use and moderate alcohol drinking on immunogenicity to coronavirus disease (COVID–19) vaccines remain elusive. This study aimed to examine the association of tobacco product use and alcohol consumption with anti–SARS–CoV–2 spike IgG antibody titers after the BNT162b2 vaccine. Methods: Participants were 3,457 fully vaccinated healthcare workers in the 4 national centers for advanced medical and research in Japan. Smoking status and alcohol consumption were assessed via a questionnaire, and anti–SARS–CoV–2 spike IgG titers were measured by chemiluminescent enzyme immunoassay using serum collected on the median of 64 days after the second vaccination. Multilevel linear regression models were used to estimate the geometric mean titers (GMT) and the ratios of means (RoM) between groups. Results: Of vaccinated participants, 99.5% (3,440/3,457) were seropositive. Compared with never-smokers (GMT=119), IgG antibody titers were significantly lower among HNB tobacco users (including those who also smoked cigarettes) (GMT=105; RoM=0.88 [95%CI: 0.78–0.99]) and exclusive cigarettes smokers (GMT=96; RoM=0.81 [95%CI: 0.71–0.92]). Compared with non-drinkers of alcohol (GMT=123), alcohol drinkers consuming <1 go/day (GMT=114; RoM=0.93 [95%CI: 0.88–0.98]), 1–1.9 go/day (GMT=105; RoM=0.85 [95%CI: 0.79–0.93]), and ≥2 go/day (GMT=101; RoM=0.82 [95%CI: 0.72–0.94]) had significantly lower antibody titers (P for trend<0.01). Spline analysis showed a large reduction of antibody until around 1 go/day of alcohol consumption, and then they gradually decreased. Conclusions: Results suggest that in addition to conventional cigarette smoking and heavy alcohol drinking, use of HNB tobacco products and moderate alcohol drinking may be predictors of lower immunological response to COVID–19 vaccine.

scholarly journals Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers

2021 ◽  
Vol 9 (8) ◽  
pp. 1725
Author(s):  
Niki Vassilaki ◽  
Antonios N. Gargalionis ◽  
Anastasia Bletsa ◽  
Nikolaos Papamichalopoulos ◽  
Elisavet Kontou ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Venous Blood ◽  
Age Groups ◽  
Vaccine Dose ◽  
Humoral Response ◽  
Continuous Variables ◽  
Igg Antibody ◽  
Female Population ◽  
Significant Difference ◽  
Antibody Titers

Anti-SARS-CoV-2 spike RBD (receptor-binding domain) IgG antibody levels were monitored in 1643 volunteer healthcare workers of Eginition, Evangelismos, and Konstantopoulio General Hospitals (Athens, Greece), who underwent vaccination with two doses of COVID-19 BNT162b2 mRNA vaccine (Pfizer) and had no history of SARS-CoV-2 infection. Venous blood was collected 20–30 days after the second vaccine dose and anti-RBD IgG levels were determined using CMIA SARS-CoV-2 IgG II Quant (Abbott) on ARCHITECT i System or ADVIA Centaur SARS-CoV-2 IgG (Siemens) on Centaur XP platform. From the total population of 1643 vaccinees (533 M/1110 F; median age = 49; interquartile range-IQR = 40–56), 1636 (99.6%) had anti-SARS-CoV-2 IgG titers above the positivity threshold of the assay used. One-Way ANOVA Kruskal-Wallis H test showed a statistically significant difference in the median of antibody titers between the different age groups (p < 0.0001). Consistently, Spearman’s correlation coefficient (r) for IgGs and age as continuous variables was −0.2380 (p = 1.98 × 10−17). Moreover, antibody titers were slightly higher by 1.2-mean fold (p = 3 × 10−6) in the total female population of the three hospitals (median = 1594; IQR = 875–2584) as compared to males (median = 1292; IQR = 671.9–2188). The present study supports that BNT162b2 vaccine is particularly effective in producing high anti-SARS-CoV-2 IgG levels in healthy individuals, and this humoral response is age- and gender-dependent.

scholarly journals Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Farhang Babamahmoodi ◽  
Majid Saeedi ◽  
Reza Alizadeh-Navaei ◽  
Akbar Hedayatizadeh-Omran ◽  
Seyed Abbas Mousavi ◽  
...  
Keyword(s):  
Side Effects ◽  
Health Care Workers ◽  
Healthcare Workers ◽  
Neutralizing Antibody ◽  
Detectable Level ◽  
Common Side Effect ◽  
Independent Evidence ◽  
Randomized Controlled ◽  
Care Workers ◽  
The Mean

AbstractThe Sputnik V is a COVID- 19 vaccine developed by the Gamalia institute of epidemiology and microbiology and released on August 11, 2020. We provided independent evidence on side effects and immunogenicity following the administration of the Sputnik V COVID-19 in Iran. In this observational study, the healthcare workers who were vaccinated with the Sputnik V COVID-19 vaccine within February and April 2021 were evaluated. Among a total of 13,435 vaccinated healthcare workers, we received 3236 self-declaration reports of Sputnik V associated adverse events with the mean age 39.32 ± 10.19 years old which 38.8% were men and 61.2% were women. Totally 68.8% of females versus 66.2% of males reported side effects after receiving the first dose and 31.2% of females versus 33.8% of males reported side effects after the second dose of vaccine. The most common side effect was a pain in the injection site (56.9%), fatigue (50.9%), body pain (43.9%), headache (35.7%), fever (32.9%), joint pain (30.3%), chilling (29.8%) and drowsiness (20.3%). Side effects of the vaccine were significantly more frequent in females and younger individuals. Among a total of 238 participants, more than 90% after the first and second dose of vaccine had a detectable level of SARS-CoV-2 RBD antibody and SARS-CoV-2 neutralizing antibody. Although the overall rate of adverse effects was higher than the interim results from randomized controlled trials, our findings support the manufacturer’s reports about the high humoral immunogenicity of vaccine against COVID-19.

scholarly journals Identification of Immunogenic Antigens of Naegleria fowleri Adjuvanted by Cholera Toxin

Pathogens ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 460
Author(s):  
Saúl Rojas-Hernández ◽  
Mara Gutiérrez-Sánchez ◽  
Diego Alexander Rojas-Ortega ◽  
Patricia Bonilla-Lemus ◽  
Arturo Contis-Montes de Oca ◽  
...  
Keyword(s):  
Immune Response ◽  
Survival Rate ◽  
Cholera Toxin ◽  
Intranasal Administration ◽  
Naegleria Fowleri ◽  
Igg Antibody ◽  
Western Blot Assay ◽  
Humoral Immune ◽  
The Third ◽  
Nægleria Fowleri

The intranasal administration of Naegleria fowleri lysates plus cholera toxin (CT) increases protection against N. fowleri meningoencephalitis in mice, suggesting that humoral immune response mediated by antibodies is crucial to induce protection against the infection. In the present study, we applied a protein analysis to detect and identify immunogenic antigens from N. fowleri, which might be responsible for such protection. A Western blot assay of N. fowleri polypeptides was performed using the serum and nasal washes from mice immunized with N. fowleri lysates, either alone or with CT after one, two, three, or four weekly immunizations and challenged with trophozoites of N. fowleri. Immunized mice with N. fowleri plus CT, after four doses, had the highest survival rate (100%). Nasal or sera IgA and IgG antibody response was progressively stronger as the number of immunizations was increased, and that response was mainly directed to 250, 100, 70, 50, 37, and 19 kDa polypeptide bands, especially in the third and fourth immunization. Peptides present in these immunogenic bands were matched by nano-LC–ESI-MSMS with different proteins, which could serve as candidates for a vaccine against N. fowleri infection.

scholarly journals Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2

2021 ◽  
Author(s):  
María Noel Badano ◽  
Florencia Sabbione ◽  
Irene Keitelman ◽  
Matias Pereson ◽  
Natalia Aloisi ◽  
...  
Keyword(s):  
Single Dose ◽  
Sharp Increase ◽  
Healthcare Workers ◽  
Humoral Response ◽  
Igg Antibody ◽  
Antibody Titers ◽  
Humoral Responses ◽  
Antibody Levels ◽  
Over Time

AbstractSARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare workers with or without exposure to SARS-CoV-2, who underwent vaccination with BBIBP-CorV (Sinopharm) vaccine in Argentina.Seroconversion rates in unexposed subjects after the first and second doses were 40% and 100%, respectively, showing a significant increase in antibody concentrations from dose 1 to dose 2 (p<0.0001).The highest antibody concentrations were found in younger subjects and women, remaining significantly associated in a multivariable linear regression model (p=0.005).A single dose of the BBIBP-CorV vaccine induced a strong antibody response in individuals with prior SARS-CoV-2infection, while a second dose did not increase this response. A sharp increase in antibody concentrations was observed following SARS-CoV-2 infection in those participants who became infected after the first and second doses (p=0.008).Individuals with SARS-CoV-2 exposure prior to vaccination showed significantly higher anti-spike IgG antibody levels, at all-time points, than those not exposed (p<0.001). Higher antibody titers were induced by a single dose in previously SARS-CoV-2 infected individuals than those induced in naïve subjects by two doses of the vaccine (p<0.0001). Three months after the second dose both groups showed a decline in antibody levels, being more abrupt in unexposed subjects.Overall, our results showed a trend towards lower antibody concentrations over time following BBIBP-CorV vaccination. Sex and age seem to influence the magnitude of the humoral response in unexposed subjects while the combination of exposure to SARS-CoV-2 plus vaccination, whatever the sequence of the events was, produced a sharp increase in antibody levels.Evaluation of the humoral responses over time and the analysis of the induction and persistence of memory B and T cell responses, are needed to assess long-term immune protection induced by BBIBP-CorV vaccine.

scholarly journals Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Cesheng Li ◽  
Ding Yu ◽  
Xiao Wu ◽  
Hong Liang ◽  
Zhijun Zhou ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Neutralizing Antibody ◽  
Binding Domain ◽  
Immune Memory ◽  
Strong Positive Correlation ◽  
Receptor Binding Domain ◽  
Igg Antibody ◽  
Humoral Immune ◽  
Positive Rate ◽  
Antibody Titers

AbstractTo investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.

scholarly journals Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third booster dose of vaccination

2021 ◽  
Author(s):  
Xiaoqi Yu ◽  
Dong Wei ◽  
Wenxin Xu ◽  
Yulong Li ◽  
Xinxin Li ◽  
...  
Keyword(s):  
Immune Response ◽  
Healthcare Workers ◽  
Booster Dose ◽  
Wild Type Strain ◽  
Serum Antibody ◽  
Booster Vaccination ◽  
Neutralization Assay ◽  
The Third ◽  
Fold Reduction ◽  
Increased Risk

The Omicron Variant of concern (B.1.1.529) has spread internationally and is raising serious concerns about the reduced vaccine efficacy and the increased risk of reinfection. Here we assessed the serum neutralizing activity using a pseudovirus-based neutralization assay in 292 healthcare workers who had administered a third homologous boosting vaccination 8 to 9 months after completion of the priming two-dose inactivated vaccination to investigate whether the newly identified Omicron variant could escape serum antibody neutralization elicited by the booster vaccination. The third booster dose with BBIBP-CorV lead to a significant rebound in neutralizing immune response against SARS-CoV-2, and the neutralization GMT on day 28 after the third booster dose was 6.1 times higher than the GMT on day 28 after the second dose. The Omicron variant did cause significantly lower neutralization sensitivity compared to the wild-type strain of the booster elicited serum, with about 20.1-fold reduction. Our study demonstrated that a third booster dose of BBIBP-CorV lead to a significant rebound in neutralizing immune response against SARS-CoV-2, while the Omicron variant showed extensive but incomplete escape of the booster elicited neutralization.

scholarly journals Antibody Titers of Dairy Heifers following Vaccination with a Staphylococcal Toxoid

1969 ◽  
Vol 49 (1) ◽  
pp. 88-98
Author(s):  
José D. Rivera Anaya ◽  
Carlos M. Berrocal ◽  
G. Rosado Carbó
Keyword(s):  
Booster Dose ◽  
Milk Whey ◽  
Dairy Heifers ◽  
The Third ◽  
Serum Titer ◽  
Steep Decrease ◽  
Antibody Titers ◽  
General Average ◽  
Level 1 ◽  
Observation Period

Five milliliters of Slanetz No. 7 Staphylococcal Toxoid were injected intramuscularly into 43 pregnant heifers in 3 herds; a booster dose was given 1 month later. The antibody level in both the blood sera and the milk wheys of these heifers was determined through a 13-month period. The average blood-serum titer reached a 1:50 level 1 month after vaccination, and remained around that level until the fifth postvaccinal month. Thereafter, a continuous and rapid decrease in titer was observed until the 11th postvaccinal month. An increase in titer was observed after the annual booster dose was given. Although the staphylococcal antibody titers in milk wheys from two herds showed a peak in the third month, the levels went steeply down at the 5th-month observation. The general average trend was a steady and steep decrease in milk-whey antibody titer through the 11-month postvaccinal observation period, with a very feeble response after the annual booster dose.

Sign in / Sign up

Export Citation Format

Share Document